R&D

LUCENT Biopharma's Medical Director Matthew Goodman, a doctor by training, specialises in late-phase Clinical Development and Medical Affairs.

News

For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

Digital

Protocol documentation will become protocol ingestion – an approach that’s automated, consistent, and intelligent.

News

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that combines in silico and wet-lab work in a single application.

R&D

Rare neurology is not defined by a lack of scientific opportunity or capital.

R&D

Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.